Scholarlink

<p>Cardiac rhabdomyomas are the most common pediatric cardiac tumors and are frequently associated with tuberous sclerosis complex (<i>TSC</i>). Large fetal cardiac rhabdomyomas causing inflow or outflow obstruction can lead to hemodynamic compromise and arrhythmias, sometimes necessitating emergent perinatal interventions. We present the fetus of a 32-year-old with multiple intracardiac rhabdomyomas identified at 23&#xa0;weeks gestation. The largest, located in the left atrium (LA), enlarged by 32&#xa0;weeks, causing mitral inflow obstruction and moderate mitral regurgitation (MR). Maternal sirolimus therapy was initiated, leading to tumor regression and permitting delivery at 39&#xa0;weeks without the need for fetal or neonatal surgery. Postnatally, the infant developed hemodynamically significant refractory arrhythmias, requiring antiarrhythmics and inotropic support. Continued sirolimus therapy further reduced tumor burden and improved MR. This case adds to the growing evidence supporting transplacental sirolimus therapy (mTOR inhibition) for managing large, hemodynamically significant fetal cardiac rhabdomyomas. It also underscores the importance of anticipating and aggressively managing associated arrhythmias.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Management of a Large Rhabdomyoma with Sirolimus and Antiarrhythmic Agents

  • 期刊论文

  • 发表日期：

    2025年9月27日

查看全文
  • Mats Steffi Jennifer Masilamani,
  • Talha Niaz,
  • Philip L. Wackel,
  • Justin M. Horner,
  • Frank Cetta,
  • Patrick W. O’Leary,
  • M. Yasir Qureshi

摘要

Cardiac rhabdomyomas are the most common pediatric cardiac tumors and are frequently associated with tuberous sclerosis complex (TSC). Large fetal cardiac rhabdomyomas causing inflow or outflow obstruction can lead to hemodynamic compromise and arrhythmias, sometimes necessitating emergent perinatal interventions. We present the fetus of a 32-year-old with multiple intracardiac rhabdomyomas identified at 23 weeks gestation. The largest, located in the left atrium (LA), enlarged by 32 weeks, causing mitral inflow obstruction and moderate mitral regurgitation (MR). Maternal sirolimus therapy was initiated, leading to tumor regression and permitting delivery at 39 weeks without the need for fetal or neonatal surgery. Postnatally, the infant developed hemodynamically significant refractory arrhythmias, requiring antiarrhythmics and inotropic support. Continued sirolimus therapy further reduced tumor burden and improved MR. This case adds to the growing evidence supporting transplacental sirolimus therapy (mTOR inhibition) for managing large, hemodynamically significant fetal cardiac rhabdomyomas. It also underscores the importance of anticipating and aggressively managing associated arrhythmias.